We studied retrospectively levels of antimyelin antibody in a group of 13 multiple sclerosis patients who underwent a clinical trial of long-term, high dose (2.0-4.5 mg/kg/day) azathiaprine therapy. In apparent contrast with collagen vascular disease associated with antitissue antibody, azathiaprine therapy was not associated with significant change in titres of antimyelin antibody. Variation of titre of antimyelin antibody in apparent association with disease activity continued during therapy. No significant changes occurred in levels of serum immunoglobulins.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.